Literature DB >> 7962659

Quantification of HIV by PCR in monocytes and lymphocytes in patients receiving antiviral treatment and low dose recombinant human granulocyte macrophage colony stimulating factor.

F D Davison1, R S Kaczmarski, A Pozniak, G J Mufti, S Sutherland.   

Abstract

Neutropenia induced by antiviral treatment, in particular AZT, can be improved with recombinant human granulocyte macrophage colony stimulating factor (RHGMCSF) in HIV positive patients. However, there has been concern that this may increase the HIV load in the mononuclear cells of such patients. Five patients receiving AZT plus low dose RHGMCSF are reported. There was no consistent change in the levels of HIV DNA in the monocytes and lymphocytes. Additionally, all patients had stable disease with no opportunistic infection during the study period. It is concluded, therefore, that low dose RHGMCSF does not significantly change the viral DNA load in patients receiving AZT.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962659      PMCID: PMC494947          DOI: 10.1136/jcp.47.9.855

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Cytokines alter production of HIV-1 from primary mononuclear phagocytes.

Authors:  Y Koyanagi; W A O'Brien; J Q Zhao; D W Golde; J C Gasson; I S Chen
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

2.  DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells.

Authors:  C Y Ou; S Kwok; S W Mitchell; D H Mack; J J Sninsky; J W Krebs; P Feorino; D Warfield; G Schochetman
Journal:  Science       Date:  1988-01-15       Impact factor: 47.728

Review 3.  Pathophysiology and management of HIV-associated hematologic disorders.

Authors:  D T Scadden; L I Zon; J E Groopman
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

4.  Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine.

Authors:  C F Perno; R Yarchoan; D A Cooney; N R Hartman; D S Webb; Z Hao; H Mitsuya; D G Johns; S Broder
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

5.  HIV-1 plasma viraemia quantification: a non-culture measurement needed for therapeutic trials.

Authors:  M G Semple; S Kaye; C Loveday; R S Tedder
Journal:  J Virol Methods       Date:  1993-02       Impact factor: 2.014

6.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

7.  Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.

Authors:  E J Duh; W J Maury; T M Folks; A S Fauci; A B Rabson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes.

Authors:  Y Li; J C Kappes; J A Conway; R W Price; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

  8 in total
  2 in total

1.  Quantification of HIV DNA in the brain by PCR: differences between fresh frozen and formalin fixed tissue.

Authors:  F Davison; S F An; F Scaravilli
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

Review 2.  Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy.

Authors:  Maria Petrina; Jacqueline Martin; Sameh Basta
Journal:  Cytokine Growth Factor Rev       Date:  2021-01-09       Impact factor: 7.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.